Evolution from double to triple-antimalarial drug combinations

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 3, 2014, Pages 182-188

  Dennis Shanks, G ^a,b   Edstein, Michael D ^a,b   Jacobus, David ^c  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Jacobus Pharmaceutical Co Inc   (United States)

Author keywords

Antimalarial drugs; Chemotherapy; Combination drug therapy; Malaria

Indexed keywords

0Z 439; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; CHLORPROGUANIL PLUS DAPSONE; CIPARGAMIN; DAPSONE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; DSM 265; FERROQUINE; KAF 156; MEFLOQUINE; MEPACRINE; MMV 390048; PAMAQUINE; PRIMAQUINE; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SULFADOXINE; SULFAFURAZOLE; TAFENOQUINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; DRUG EFFICACY; HUMAN; MALARIA; MALARIA FALCIPARUM; MONOTHERAPY; NONHUMAN; POLYPHARMACY; SOUTHEAST ASIA; WAR; DRUG COMBINATION; DRUG RESISTANCE; PROCEDURES;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; QUINOLINES;

EID: 84925622788     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru199     Document Type: Article

References (60)

1. Burrows JN, van Huijsduijnen RH, Mohrle JJ et al. Designing the next generation of medicines for malaria control and eradication. Designing the next generation of medicines for malaria control and eradication 2013;12:187.
2. Some AF, Sere YY, Dokomajilar C et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso 2010;54:1949-54.
3. Carrara VI, Lwin KM, Phyo AP et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med 2013;10:e1001398.
4. Maude RJ, Socheat D, Nguon C et al. Optimising strategies forPlasmodium falciparum malaria elimination in Cambodia:primaquine, mass drug administration and artemisinin resistance. PloS One 2012;7:e37166.
5. Bruce-Chwatt L. Essential malariology. London: William Heinemann; 1980.
6. Dunn C. Some observations on the therapeutics of malaira in Ceylon. Some observations on the therapeutics of malaira in Ceylon 1936;30:233-44.
7. Baird JK, Hoffman SL. Primaquine therapy for malaria. Primaquine therapy for malaria 2004;39:1336-45.
8. Alving A, Eichelberger L, Arnold J, Edgcomb J. The clinical testing of antimalarial drugs at Statesville Penitentary. Washington DC: US NIH; 1949.
9. Baird KJ, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Diagnosis and treatment of Plasmodium vivax malaria 2012;80:203-70.
10. Marcsisin SR, Jin X, Bettger Tet al. CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever. Malaria J 2013;12:214.
11. Bennett JW, Pybus BS, Yadava A et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria 2013;369:1381-2.
12. Myint HY, Berman J, Walker L et al. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations 2011;85:1010-4.
13. Ognibene A, Conte N. Malaria chemotherapy. In: Ognibene A, Barrett O, editors. Internal medicine in Vietnam. Washington DC: Govt Printing Office; 1982.
14. Hall AP, Doberstyn EB, Mettaprakong V, Sonkom P. Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine. Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine 1975;2:15-7.
15. de Souza JM, Sheth UK, de Oliveira RM et al. A phase I clinical trial of Fansimef (mefloquine plus sulfadoxine-pyrimethamine) in Brazilian male subjects. A phase I clinical trial of Fansimef (mefloquine plus sulfadoxine-pyrimethamine) in Brazilian male subjects 1985;63:611-5.
16. Hall AP, Doberstyn EB, Karnchanachetanee C et al. Sequential treatment with quinine and mefloquine or quinine and pyrimethaminesulfadoxine for falciparum malaria. Sequential treatment with quinine and mefloquine or quinine and pyrimethaminesulfadoxine for falciparum malaria 1977;1:1626-8.
17. de Souza JM, Sheth UK, Wernsdorfer WH et al. A phase II/III doubleblind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria. A phase II/III doubleblind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria 1987;65:357-61.
18. Tin F, Hlaing N, Tun T et al. Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma. Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma 1985;63:727-30.
19. Harinasuta T, Bunnag D, Vanijanond S et al. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose 1987;65:363-7.
20. Tin F, Nyunt H, Lim MA et al. Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma. Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma 1987;81:910-2.
21. Nosten F, Imvithaya S, Vincenti M et al. Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxinepyrimethamine. Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxinepyrimethamine 1987;65:891-6.
22. Ezedinachi EN, Ekanem OJ, Chukwuani CM et al. Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum. Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum 1999;61:114-9.
23. Phyo AP, Nkhoma S, Stepniewska K et al. Emergence of artemisinresistant malaria on the western border of Thailand: a longitdinal study. Emergence of artemisinresistant malaria on the western border of Thailand: a longitdinal study 2012;379:1960-6.
24. WHO. World Malaria Report 2013. Geneva: World Health Organization; 2014.
25. Basco LK, Ngane VF, Ndounga M et al. Molecular epidemiology of malaria in Cameroon. Molecular epidemiology of malaria in Cameroon 2006;75:388-95.
26. Mutabingwa TK, Anthony D, Heller A et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial 2005;365:1474-80.
27. Staedke SG, Kamya MR, Dorsey G et al. Amodiaquine, sulfadoxine/ pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Amodiaquine, sulfadoxine/ pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial 2001;358:368-74.
28. Basco LK, Same-Ekobo A, Ngane VF et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxinepyrimethamine- amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxinepyrimethamine- amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon 2002;80:538-45.
29. Dorsey G, Njama D, Kamya MR et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial 2002;360:2031-8.
30. Mutabingwa TK, Muze K, Ord R et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PloS One 2009;4:e5138.
31. Obonyo CO, Juma EA, Ogutu BR et al. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis 2007;101:117-26.
32. Anthony MP, Burrows JN, Duparc S et al. The global pipeline of new medicines for the control and elimination of malaria. The global pipeline of new medicines for the control and elimination of malaria 2012;11:316.
33. Clark TD, Njama-Meya D, Nzarubara B et al. Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children 2010;5:e11759.
34. Song J, Socheat D, Tan B et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine 2010;9:57.
35. Premji Z, Umeh RE, Owusu-Agyei S. Chlorproguanil-dapsoneartesunate versus artemether-lumefantrine: a randomized, doubleblind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. Chlorproguanil-dapsoneartesunate versus artemether-lumefantrine: a randomized, doubleblind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria 2009; 4:e6682.
36. Tiono A, Dicko A, Ndububa D et al. Chlorproguanil-dapsone-artesunate versus Chlorproguanil-dapson: a randomized, double-bline, phase III trial in African children, adolescents and adults with uncomplicated Plasmodium falciparum malaria. Chlorproguanil-dapsone-artesunate versus Chlorproguanil-dapson: a randomized, double-bline, phase III trial in African children, adolescents and adults with uncomplicated Plasmodium falciparum malaria 2009;81:969-78.
37. Pamba A, Richardson ND, Carter N et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone 2012;120:4123-33.
38. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics 2010;376:739-41.
39. Teuscher F, Chen N, Kyle DE et al. Phenotypic changes in artemisininresistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Phenotypic changes in artemisininresistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition 2012;56:428-31.
40. Teuscher F, Gatton ML, Chen N et al. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure 2010;202:1362-8.
41. Wells TN. Discovering and developing new medicines for malaria control and elimination. Discovering and developing new medicines for malaria control and elimination 2013; 13:292-302.
42. White N. Malaria. In: Cook G and Zumla A, editors. Manson's Tropical Diseases 22 ed. London: Saunders; 2009.
43. Gujjar R, El Mazouni F, White KL et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice 2011;54:3935-49.
44. Gujjar R, Marwaha A, El Mazouni F et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice 2009; 52:1864-72.
45. Kreidenweiss A, Kremsner PG, Dietz K, Mordmuller B. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum 2006; 75:1178-81.
46. Pomel S, Biot C, Bories C, Loiseau PM. Antiprotozoal activity of ferroquine. Antiprotozoal activity of ferroquine 2013;112:665-9.
47. Mombo-Ngoma G, Supan C, Dal-Bianco MP et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine-a candidate anti-malarial drug-in adults with asymptomatic Plasmodium falciparum infection. Phase I randomized dose-ascending placebo-controlled trials of ferroquine-a candidate anti-malarial drug-in adults with asymptomatic Plasmodium falciparum infection 2011;10:53.
48. Supan C, Mombo-Ngoma G, Dal-Bianco MP et al. Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections. Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections 2012;56:3165-73.
49. Maser P, Wittlin S, Rottmann M et al. Antiparasitic agents: new drugs on the horizon. Antiparasitic agents: new drugs on the horizon 2012;12:562-6.
50. Rottmann M, McNamara C, Yeung BK et al. Spiroindolones, a potent compound class for the treatment of malaria. Spiroindolones, a potent compound class for the treatment of malaria 2010;329:1175-80.
51. van Pelt-Koops JC, Pett HE, Graumans Wet al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector 2012;56:3544-8.
52. White N, Pukrittayakamee S, Phyo AP et al. Spiroindolone KAE609 for falciparum and vivax malaria. Spiroindolone KAE609 for falciparum and vivax malaria 2014;371:403-10.
53. Charman SA, Arbe-Barnes S, Bathurst IC et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria 2011;108:4400-5.
54. Moehrle JJ, Duparc S, Siethoff C et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials 2013;75:24-37.
55. Kuhen KL, Chatterjee AK, Rottmann M et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment and prevention of disease transmission. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment and prevention of disease transmission 2014;58:5060-7.
56. Shanks GD, Oloo AJ, Aleman GM et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria 2001; 33:1968-74.
57. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study 2014;83:1049-58.
58. Walsh DS, Wilairatana P, Tang DB et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse 2004;39:1095-103.
59. Tahar R, Almelli T, Debue C et al. Randomized trial of artesunateamodiaquine, atovaquone-proguanil, and artesunate-atovaquoneproguanil for the treatment of uncomplicated falciparum malaria in Children. Randomized trial of artesunateamodiaquine, atovaquone-proguanil, and artesunate-atovaquoneproguanil for the treatment of uncomplicated falciparum malaria in Children 2014;21:1962-71.
60. Winter K, Hastings IM. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure 2011;55:3380-92.